|
Patent landscape, scope, and claims: |
United States Patent 8,536,130 Scope, Claims, and US Patent Landscape for (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol
US Patent 8,536,130 covers a narrow, use-based therapeutic claim set focused on treating polyneuropathic pain (including diabetic and peripheral diabetic polyneuropathy subsets) by administering (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol (free base or hydrochloride salt). The claim scope is limited to methods of treatment (not composition, not dosage regimens, not manufacturing), and the patent’s practical value depends on the existence and strength of additional claims in related family members covering formulation, dosing, and/or stereochemical composition.
Claim-set at a glance (US 8,536,130)
| Claim |
Core protected subject matter |
Key scope gates |
| 1 |
Method of treating polyneuropathic pain via administration of an effective polyneuropathic-pain inhibiting amount of the (1R,2R) phenol or a pharmaceutically acceptable salt |
Requires (i) polyneuropathic pain indication, (ii) administration, (iii) the specific stereoisomer identity, (iv) “effective amount” functional limitation |
| 2 |
Same method but specifically with the hydrochloride salt |
Limits to hydrochloride form (still method-based) |
| 3 |
Diabetic polyneuropathic pain subset |
Narrows indication to diabetic polyneuropathy-related pain |
| 4 |
Peripheral polyneuropathic pain subset |
Narrows anatomical descriptor to peripheral pain |
| 5 |
Peripheral diabetic polyneuropathic pain subset |
Narrows to overlap subset |
| 6 |
Method treating diabetic polyneuropathy via administration of a pharmacologically effective amount of the (1R,2R) phenol or salt |
Separate dependent structure tied to diabetic polyneuropathy (broader “diabetic polyneuropathy” label than “pain” wording) |
Immediate implication for freedom-to-operate (FTO): Any US marketing activity that performs or induces use of this stereochemically defined compound for polyneuropathic pain treatment, including diabetic and peripheral diabetic subsets, can directly implicate method claims. Generic/comparator entry risk is driven by whether the generic’s label (or physician practice encouraged by promotional materials) includes the same method-of-use language that maps to claims 1, 3, 4, 5, and 6.
What does US patent 8,536,130 claim coverage actually protect?
Answer: It protects method-of-treatment claims using a specific stereoisomer of a phenol, for polyneuropathic pain and diabetic polyneuropathy, including a dedicated dependent claim to the hydrochloride salt.
Independent claim 1 scope: functional method-of-treatment coverage
Claim 1 is a classic “administration to treat” method-of-use claim.
Essential elements to infringe (practical claim-mapping):
- A “subject” suffering polyneuropathic pain.
- Administration of an “effective polyneuropathic pain inhibiting amount.”
- The administered agent is the specific compound: (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt.
- The compound must be the same stereochemical configuration indicated in the claim. If a developer uses a mixture or a different stereoisomeric composition, infringement turns on whether the administered compound “is” the claimed stereoisomer or “a salt thereof” meeting the stereochemical requirement.
Dependent claim 2: hydrochloride salt form
Claim 2 narrows the same method to “administering a hydrochloride salt.” In practical terms:
- If a product uses a different pharmaceutically acceptable salt (e.g., maleate, fumarate, HCl in other salt forms, etc.), claim 2 may not apply.
- If a product is specifically the hydrochloride salt, claim 2 increases certainty of mapping.
Dependent claims 3–5: indication narrowing
These claims specify pain descriptors:
- Claim 3: diabetic polyneuropathic pain
- Claim 4: peripheral polyneuropathic pain
- Claim 5: peripheral diabetic polyneuropathic pain
Practical effect: Even if a competitor can argue that its use does not fit “polyneuropathic pain” broadly, the existence of multiple narrowing claims reduces design-around space if the competitor’s target populations align with diabetic and/or peripheral diabetic polyneuropathic pain.
Claim 6: diabetic polyneuropathy (not limited to “pain” phrasing)
Claim 6 uses “treating diabetic polyneuropathy,” requiring administration of the same stereoisomer or salt in a pharmacologically effective amount.
Practical effect: Depending on claim construction and label wording, claim 6 can be used to capture therapy where the clinical objective is diabetic polyneuropathy management rather than pain wording, though both claims are tightly anchored to the same administered compound identity.
Does US 8,536,130 cover the compound, the salt form, or only methods?
Answer: The claims provided are method-of-treatment claims. They do not, as written, claim the compound as a composition of matter.
Composition vs method-of-use: what these claims do not cover
Based on the claim text supplied:
- No claim is written to cover “a pharmaceutical composition comprising” the compound.
- No claim is written to cover “a dosage form” (tablet, capsule, injection).
- No claim is written to cover “a method of manufacturing.”
- No claim is written to cover a dosing regimen (mg range, titration, frequency) beyond “effective amount.”
Business consequence: If a competitor avoids the claimed method-of-use indication on labeling and marketing, infringement may be reduced, even if the compound itself is administered in other indications not mapped to claims 1/3/4/5/6. Conversely, if the competitor’s product label and physician promotion track diabetic neuropathy and/or polyneuropathic pain, method-of-use exposure remains.
How narrow is the stereochemical scope of US 8,536,130?
Answer: The claims are stereospecific. They require administration of (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt.
Why stereochemistry matters in enforcement
From an infringement and product design standpoint, stereospecific claims can create a stronger boundary than “racemate” or “any stereoisomer” claims:
- A developer using different stereoisomers may argue noninfringement because the administered active ingredient is not the claimed stereoisomer.
- A developer using an isomer mixture containing the claimed stereoisomer may face risk if the claim construction treats the claimed stereoisomer as present in the administered mixture as such. Practically, risk depends on how the stereoisomer is defined in the product’s specification and whether claims are read to cover mixtures where the stereoisomer is present.
What is the indication scope: polyneuropathic pain vs diabetic polyneuropathy?
Answer: The claim set targets polyneuropathic pain and diabetic polyneuropathy management via administration of the stereospecific phenol compound.
Indication mapping table
| Claim |
Indication language |
Likely clinical target |
| 1 |
“polyneuropathic pain” |
Neuropathic pain states with polyneuropathy etiology |
| 3 |
“diabetic polyneuropathic pain” |
Pain in diabetic polyneuropathy |
| 4 |
“peripheral polyneuropathic pain” |
Peripheral nerve pain with polyneuropathy |
| 5 |
“peripheral diabetic polyneuropathic pain” |
Overlap: diabetic + peripheral polyneuropathic pain |
| 6 |
“diabetic polyneuropathy” |
Disease-state management; may include pain, but claim text is not confined to pain |
Design-around reality check
- If a competitor’s indication is limited to something like “neuropathy of non-diabetic etiology” or “central neuropathic pain” and avoids diabetic/peripheral polyneuropathic pain, it may reduce mapping to claims 1/3/4/5 and potentially claim 6.
- If a competitor’s label includes diabetic polyneuropathy and/or neuropathic pain consistent with claim language, the method-of-use risk increases.
What patent landscape typically surrounds a US method-of-use patent like 8,536,130?
Answer: Method-of-use claims for a specific stereochemical active ingredient commonly sit in a family that also includes related claims for:
- compound identity (composition-of-matter),
- stereochemical definitions,
- specific salt forms,
- formulations and dosage forms,
- dosing regimens,
- additional therapeutic indications.
However: Only the claim text of US 8,536,130 is provided here. The existence, numbers, and strength of other family members cannot be established from the input.
Practical landscape implications (without family-member confirmation)
- If related composition-of-matter patents exist, the method-of-use patent is a secondary enforcement lever.
- If only method-of-use exists (composition family absent or weak/expired), enforcement often concentrates on label-driven infringement and physician prescribing inducement.
Orange Book status and FDA regulatory linkage: what does US 8,536,130 imply?
Answer: The claim text indicates it would be listed only if tied to a marketed drug product with that active ingredient and if the listed method-of-use is associated with an FDA-approved indication.
But: No Orange Book listings, FDA NDA/BLA identifiers, application numbers, or reference product details are provided. The claim text alone cannot support a verified Orange Book status statement.
How strong is US 8,536,130’s enforcement posture?
Answer: Strength is tied to (i) clear mapping between the administered agent and stereochemical identity, and (ii) label/promotion alignment with polyneuropathic pain and diabetic polyneuropathy. Weaknesses stem from the method-only nature, absence of dosage-form and regimen specificity, and potential design-around via indication carveouts.
Strength drivers
- Stereochemical specificity of the administered compound in claims 1 and 6.
- Multiple dependent indication claims (diabetic, peripheral, peripheral diabetic) that broaden coverage across likely patient-label subsets.
- Salt specificity via claim 2 (hydrochloride), which can strengthen enforcement if a competitor uses HCl salt.
Litigation risk points for accused infringers
- If a generic or branded competitor markets the same active in the same indication, method claims create direct exposure.
- If promotional materials are directed to “diabetic polyneuropathic pain” or “diabetic polyneuropathy,” infringement arguments become label-anchored.
What generic entry risks exist for products using this stereoisomer?
Answer: If a competitor product uses the same stereospecific active ingredient and targets polyneuropathic pain, especially diabetic and peripheral diabetic subsets, it faces method-of-use claim exposure.
Risk scenarios (label and practice dependent)
| Scenario |
Likely mapping to US 8,536,130 |
| Generic seeks label including diabetic polyneuropathic pain |
High risk: claims 1 and 3 (and potentially 5) map closely |
| Generic label includes diabetic polyneuropathy (with or without pain emphasis) |
Risk for claim 6; also potential mapping to claim 1 depending on wording |
| Generic label excludes diabetic/peripheral polyneuropathic pain and targets other neuropathies |
Lower risk, but mapping depends on whether “polyneuropathic pain” is still encompassed |
| Competitor uses non-hydrochloride salt |
Claim 2 may be avoidable; claims 1/3–6 remain if they accept “pharmaceutically acceptable salt” |
Key Takeaways
- US Patent 8,536,130 is a method-of-treatment patent, not a composition or dosage-form patent, based on the provided claims.
- The core protected subject matter is administering (1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol (or a pharmaceutically acceptable salt) to treat polyneuropathic pain and diabetic polyneuropathy.
- Dependent claims narrow coverage to diabetic, peripheral, and peripheral diabetic polyneuropathic pain, plus a hydrochloride salt variant.
- Enforcement and generic entry risk hinge on stereoisomer identity and FDA label/promotion language aligning with polyneuropathic pain and diabetic polyneuropathy.
FAQs
-
Can a product avoid US 8,536,130 by using a different salt than hydrochloride?
Claim 2 is hydrochloride-specific, but claims 1 and 6 cover “pharmaceutically acceptable salt,” so a different salt may not avoid infringement.
-
Does US 8,536,130 require the patient to have “pain” vs “disease”?
Claims 1 and 3–5 require polyneuropathic pain; claim 6 covers diabetic polyneuropathy and is not limited to pain wording.
-
If a product’s indication is “peripheral neuropathy” without “polyneuropathic pain,” is it safe?
Infringement turns on claim construction and whether the labeled or practiced use matches “polyneuropathic pain” language in claims 1/4/5.
-
Would using the same compound but a different stereoisomer avoid infringement?
The claims recite (1R,2R) stereochemistry, so a different stereoisomeric active ingredient can be a noninfringement pathway if it is not the claimed stereoisomer.
-
Does US 8,536,130 claim a dosing regimen?
The provided claims require an “effective” amount but do not specify mg ranges, titration, or frequency.
References (APA)
- United States Patent 8,536,130 (claims as provided by user).
More… ↓
⤷ Start Trial
|
